



Universiteit
Leiden

The Netherlands

Disrupting the transcriptional machinery to combat triple-negative breast cancer

Noord, V.E. van der

Citation

Noord, V. E. van der. (2024, April 25). *Disrupting the transcriptional machinery to combat triple-negative breast cancer*. Retrieved from <https://hdl.handle.net/1887/3748390>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3748390>

Note: To cite this publication please use the final published version (if applicable).

Disrupting the transcriptional machinery to combat triple-negative breast cancer

Vera Evita van der Noord

Cover design: Roshni R. Nair

Thesis lay-out: Vera E. van der Noord

Printing: Ipskamp Printing, on recycled paper

© Copyright, Vera E. van der Noord, 2024

ISBN: 978-94-6473-442-3

All rights reserved. No part of this book may be reproduced in any form or by any means without permission of the author.

Disrupting the transcriptional machinery to combat triple-negative breast cancer

Proefschrift

ter verkrijging van de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 25 april 2024
klokke 15:00 uur

door

Vera Evita van der Noord
geboren te Woerden, Nederland
in 1994

Promotor: Prof. dr. B. van de Water

Co-promotor: Dr. S.E. Le Dévédec

Promotiecommissie:

Prof. dr. H. Irth

Prof. dr. E.C.M de Lange

Prof. dr. J. Jonkers (Nederlands Kanker Instituut)

Prof. dr. J.W.M. Martens (Erasmus Medisch Centrum)

Prof. dr. M. Tijsterman (Leiden Universiteit Medisch Centrum)

The research described in this thesis was performed at the division Drug Discovery and Safety of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands). The research was financially supported by the Dutch Cancer Society (KWF) and the European Research Council (ERC).

Table of contents

Chapter 1	Introduction, aim and outline of this thesis	7
Chapter 2	An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer	21
Chapter 3	Targeting the heterogeneous genomic landscape in triple-negative breast cancer through inhibitors of the transcriptional machinery	49
Chapter 4	Disruption of P-TEFb activity efficiently targets triple-negative breast cancer cells and synergizes with EGFR inhibition	81
Chapter 5	Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors	111
Chapter 6	Targeting CDK9 and CDK12 to overcome transcriptional addiction in triple-negative breast cancer	151
Chapter 7	Summary, discussion and future perspectives	191
Appendix	List of abbreviations	208
	Dutch summary	211
	List of publications	216
	About the author	218